Literature DB >> 10169673

Comments on economic evaluation of chemotherapy.

S R Clausen, V Jøjnsson, M M Hansen, H Keiding, M Kjaer, B E Christensen, H Mouridsen, T Palshof, S W Hansen.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 10169673     DOI： 10.2165/00019053-199712020-00011

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  9 in total

1.  Pharmacoeconomic aspects in the treatment of curable and incurable cancer.

Authors:  V Jønsson; S R Clausen; M M Hansen
Journal:  Pharmacoeconomics       Date:  1995-10       Impact factor: 4.981

Review 2.  Cost-utility in practice: a policy maker's guide to the state of the art.

Authors:  K Gerard
Journal:  Health Policy       Date:  1992-07       Impact factor: 2.980

3.  Some guidelines on the use of cost effectiveness league tables.

Authors:  J Mason; M Drummond; G Torrance
Journal:  BMJ       Date:  1993-02-27

4.  Cost-effectiveness league tables: more harm than good?

Authors:  M Drummond; G Torrance; J Mason
Journal:  Soc Sci Med       Date:  1993-07       Impact factor: 4.634

Review 5.  An overview of adjuvant therapy for colorectal cancer.

Authors:  D G Haller
Journal:  Eur J Cancer       Date:  1995 Jul-Aug       Impact factor: 9.162

Review 6.  European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care.

Authors:  C Williams; D Coyle; A Gray; J Hutton; T Jefferson; G Karlsson; K Kesteloot; C Uyl-de Groot; S Wait
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

Review 7.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

8.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

Authors:  W P Peters; M Ross; J J Vredenburgh; B Meisenberg; L B Marks; E Winer; J Kurtzberg; R C Bast; R Jones; E Shpall
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

9.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.